BioCryst Pharmaceuticals BCRX Operating Lease Liabilities (Total)
Operating Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's operating lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's operating lease liabilities (total)?
- BioCryst Pharmaceuticals (BCRX) reported operating lease liabilities (total) of $12.98M in Q1 2026.
- How has BioCryst Pharmaceuticals's operating lease liabilities (total) changed year-over-year?
- BioCryst Pharmaceuticals's operating lease liabilities (total) increased by 46.7% year-over-year, from $8.85M to $12.98M.
- What is the long-term trend for BioCryst Pharmaceuticals's operating lease liabilities (total)?
- Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's operating lease liabilities (total) has grown at a 12.0% compound annual growth rate (CAGR), from $5.05M to $8.89M.
- What does operating lease liabilities (total) mean?
- This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.